

Supplementary table 1: DNA sequence variations in genes that may be involved in the response to infliximab.

Gen (analyzed variants)	Patient 1		Patient 2
<i>TLR2</i> rs1816702	CC		CC
<i>TLR2</i> rs3804099	CT		CT
<i>TLR4</i> rs5030728	AG		GG
<i>TLR9</i> rs352139	AG		AG
<i>LY96</i> rs11465996	CC		CC
<i>IL10</i> rs1800872	CC		CA
<i>IL10</i> rs3024505	CT		CC
<i>IL6</i> rs10499563	TC		TT
<i>TNFRSF1A</i> rs4149570	GT		TT
<i>TNFAIP3</i> rs6927172	CG		CC
<i>CD14</i> rs2569190	AG		Not performed
<i>MAP3K14</i> rs7222094	TT		Not performed
<i>TNFA</i> rs361525	GG		GG
<i>IL1B</i> rs4848306	GA		GG
<i>IL17A</i> rs2275913	GG		AA
<i>TNF1B</i> rs1061622	TT		TG
<i>TNF1B</i> rs1061624	GG		GG
<i>TNF1A</i> rs767455	CT		TT
<i>TNF</i> rs1800629	GG		GG
<i>FASL</i> rs762000	CT		Not performed
<i>FCGR3A</i> rs396991	Indeterminate		Not performed
<i>TNF1B</i> rs3397	TT		TT
Gen (analyzed variants)	Genotype		Interpretation
<i>LY96</i> (rs11465996)	CC/CG		Greater probability of long-term response to anti-TNFs
<i>TLR4</i> (rs5030728)	GG	40.7%	Probability of having infliximab levels below 3 µg / mL
	GA/AA	17%	
<i>IL10</i> (rs3024505)	CC	19%	
	CG/GG	46.5%	